Budget impact analysis of the introduction of Rosiglitazone in the treatment of type-2 diabetes. The Italian NHS perspective

被引：0
|
作者：
Novelli, M [1 ]
Avallone, A [1 ]
Frizzo, V [1 ]
Bamfi, F [1 ]
机构：
[1] GlaxoSmithKline Inc, Verona, VR, Italy
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67631-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A158 / A158
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN IN THE TREATMENT OF TYPE-2 DIABETES IN CHILE
    Elgart, J.
    Caporale, J.
    Aiello, E. C.
    Gagliardino, J. J.
    Waschbusch, M.
    Jotimliansky, L.
    Valencia, J. E.
    VALUE IN HEALTH, 2011, 14 (03) : A94 - A94
  • [2] Budget impact of rosiglitazone in type 2 diabetes
    Zaniolo, Orietta
    Bamfi, Francesco
    Iannazzo, Sergio
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2007, 8 (01) : 15 - 26
  • [3] Rosiglitazone in the treatment of patients with type 2 diabetes: Implementation of budget impact analysis software
    Zaniolo, O.
    Iannazzo, S.
    Bamfi, F.
    VALUE IN HEALTH, 2007, 10 (06) : A257 - A257
  • [4] BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES IN ARGENTINA
    Elgart, J.
    Caporale, J.
    Gagliardino, J. J.
    Waschbusch, M.
    Aiello, E. C.
    Jotimliansky, L.
    VALUE IN HEALTH, 2010, 13 (03) : A57 - A57
  • [5] BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN/METFORMIN EXTENDED-RELEASE (XR) IN THE TREATMENT OF TYPE-2 DIABETES IN CHILE
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2013, 16 (03) : A159 - A160
  • [6] Rosiglitazone, PPAR(gamma), and Type 2 Diabetes.
    Kahn, Barbara B.
    McGraw, Timothy E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (27): : 2667 - 2669
  • [7] Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy
    Iannazzo, Sergio
    Mannucci, Edoardo
    Mantovani, Lorenzo
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (01) : 19 - 27
  • [8] Type-2 diabetes. The risk of severe hypoglycemia
    Virally, Marie
    Kevorkian, Jean-Philippe
    SANG THROMBOSE VAISSEAUX, 2010, 22 (10): : 499 - 501
  • [9] Rosiglitazone reduces urinary albumin excretion in type 2 diabetes.
    Freed, MI
    Weston, WM
    Viberti, G
    DIABETOLOGIA, 1999, 42 : A230 - A230
  • [10] BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF DEXCOM ONE FOR THE TREATMENT OF PATIENTS WITH T2 DIABETES ON AN INTENSIVE INSULIN SCHEDULE FROM THE PERSPECTIVE OF THE ITALIAN HEALTHCARE PAYER
    Genugten, M.
    Grifi, M.
    VALUE IN HEALTH, 2023, 26 (12) : S53 - S53
12345